Asprosin is a novel peptide hormone produced and secreted by white adipose tissues. Asprosin associated with insulin resistance and promotes hepatic glucose production. Previous studies showed that serum asprosin was raised in the general population with polycystic ovary syndrome (PCOS). However, there were studies supporting the opposite. Also, there were studies that showed the highest levels of asprosin was due to insulin resistance, as well as in type 2 diabetes patients. PCOS is one of the metabolic disorders related to insulin resistance. Therefore, the current study aims to evaluate the levels of asprosin in the blood serum of women with PCOS compared to the healthy women who resident in Duhok in the Kurdistan Region of Iraq. A cross-sectional study was conducted from 20th of June, 2020 to 11th of January, 2021 at Obstetrics and Gynecology Hospital and Mazi medical clinics. Serum asprosin level was determined in 75 women with PCOS (18-44 years) and 96 healthy women. SPSS software was utilized for analyzing the study data. The (means ± SD) of demographic parameters (body mass index (BMI) and waist circumference (WC)) in women with PCOS were significantly highest in comparison to healthy women. The biochemical parameters (serum asprosin, fasting blood sugar (FBS), fasting insulin (FI), total cholesterol (TC), and triglyceride (TG)) in women with PCOS also were remarkably higher compared to healthy women with the exception of high-density lipoprotein- cholesterol (HDL-C). The current data show that serum asprosin variance significantly between WC, BMI, FBS, FI, TC, TG and HDL-C. The study confirms that serum asprosin in women with PCOS was higher than in the healthy women. In addition in women with PCOS it was found that serum asprosin was positively correlated with BMI, WC, FBS, FI, HOMA-IR, TC and TG (P<0.05). Except, HDL-C was negatively correlated with serum asprosin (P<0.01).